Medicare Started Covering Hemp THC Products. Now Prohibitionists Are Suing to Stop It.

On April 1st, the Centers for Medicare & Medicaid Services officially launched a program that gives eligible Medicare beneficiaries access to hemp-derived CBD and THC products at no out-of-pocket cost. By April 3rd, a federal lawsuit was filed to shut it down. That’s about as compressed a grey zone as you’ll find.

Here’s what’s actually happening — and what it means for consumers, retailers, and anyone watching federal hemp policy.

The Program: What CMS Is Offering

The CMS program, called the Substance Access Beneficiary Engagement Incentive (SABEI), was announced in December 2025 as part of a broader set of executive actions by the Trump administration on cannabis policy. The formal FAQ and program details went up in mid-March.

Under the program, Medicare beneficiaries who qualify can receive hemp-derived products — including both CBD and certain THC-containing formulations — through a CMS-administered channel. Dr. Mehmet Oz, who now heads CMS, publicly acknowledged the program’s launch on April 1st.

The products covered under SABEI must meet the program’s definition of “hemp-derived.” That’s a deliberately broad term under the 2018 Farm Bill’s original framework, which defined hemp as cannabis with no more than 0.3% delta-9 THC on a dry weight basis. Many products in the market — including gummies, tinctures, and other edibles with measurable psychoactive effect — technically qualify under that definition.

The Lawsuit: What Plaintiffs Are Arguing

A coalition of anti-drug and prohibitionist groups filed a federal lawsuit in the U.S. District Court for the District of Columbia on Tuesday, April 1st. The core arguments are procedural and substantive.

On the procedural side, plaintiffs argue CMS launched the program without going through the notice-and-comment rulemaking process required under the Administrative Procedure Act. In plain terms: they say the agency made a major policy change without letting the public weigh in, which is the normal legal requirement for federal agency action.

On the substantive side, plaintiffs argue that Congress already settled the question of which hemp products are legal. The 2025 federal spending bill — a continuing resolution passed in November 2025 — included language restricting sales of certain intoxicating hemp-derived products. Plaintiffs contend those restrictions mean the products CMS now wants to distribute no longer legally qualify as “hemp” under federal law.

That’s the grey zone in a single sentence: the executive branch’s CMS is distributing products that Congress may have already restricted.

The Court’s First Move: Restraining Order Denied

On Wednesday, April 2nd, a federal judge denied plaintiffs’ request for a temporary restraining order — the emergency mechanism that would have immediately halted the program before a full hearing.

That denial is procedurally significant. It doesn’t mean plaintiffs lose. It means the program stays active for now while the case moves forward. A judge can deny a TRO on several grounds, including a finding that the plaintiffs haven’t yet established a strong enough likelihood of irreparable harm to justify emergency intervention.

The court has scheduled a hearing on the plaintiffs’ motion for a preliminary injunction for April 20th. That hearing is the more meaningful event to watch. A preliminary injunction, if granted, would pause the program while the full legal case plays out — which could take months.

What This Means in Practice

If you’re a Medicare beneficiary: The program is active right now. If you’re eligible, you can access hemp-derived products through SABEI. That could change on or after April 20th depending on how the court rules.

If you’re a hemp retailer: This matters for your market position and your legal exposure. A federal agency actively distributing hemp THC products is a significant market signal — but it’s also a moving target. The spending bill language restricting intoxicating hemp products remains on the books. If the court sides with plaintiffs, that spending bill argument gains traction and could affect how other federal agencies interpret what’s permissible.

If you’re a compliance officer: The core tension here hasn’t been resolved — it’s been elevated. You now have two branches of the federal government pointing in opposite directions on the same product category. CMS says these products are distributable; the legislative history of the 2025 spending bill says they were meant to be restricted. That ambiguity creates real risk in any compliance program that relies on a single “federal law says hemp is legal” conclusion.

The Bigger Picture: Congress vs. Executive on Hemp

This lawsuit is the latest instance of a pattern that’s been building since 2023: Congress tightening hemp policy through spending restrictions and standalone legislation, while certain executive branch actors try to expand hemp access under existing Farm Bill authority.

The 2025 spending bill’s hemp language was a deliberate attempt by some in Congress to claw back what they saw as regulatory overreach in the hemp market — specifically targeting high-potency, intoxicating products sold in gas stations and convenience stores under the hemp label. The Trump CMS program runs in the opposite direction, treating those same products as worthy of Medicare reimbursement.

Courts generally don’t love resolving that kind of inter-branch policy disagreement on an accelerated timetable, which is one reason TRO requests in these cases often fail. But the April 20th injunction hearing is a real inflection point.

What to Watch

– April 20th, U.S. District Court for D.C.: Hearing on the preliminary injunction. If granted, SABEI pauses. If denied, the program continues while the case proceeds. – How CMS defines “eligible products”: The FAQ posted in March is still vague on which specific formulations qualify. That definition matters enormously for both enforcement and market access. – Congressional response: Whether the spending bill restriction language was intended to cover CMS-distributed products is genuinely unclear. Expect some members to weigh in publicly before the April 20th hearing.

The program is running. The lawsuit is live. The court will speak in roughly two weeks. Until then, anyone operating in this space is doing so with real legal uncertainty on both sides of the federal government.

Morgan Ellis covers hemp regulation and the grey zones where federal law, state law, and enforcement don’t align. She has previously worked as a compliance consultant for hemp and CBD brands.